Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutation-Targeted Therapy With Sunitinib or Everolimus in Advanced NETs
NCT02315625Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib and everolimus in Gastrointestinal neuroendocrine tumor and Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2015; status: terminated.
02
Drugs
sunitinibeverolimus
03
Conditions
Gastrointestinal neuroendocrine tumorPancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02315625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315625.